GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MoonLake Immunotherapeutics (NAS:MLTX) » Definitions » Change In Prepaid Assets

MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Change In Prepaid Assets : $-8.28 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is MoonLake Immunotherapeutics Change In Prepaid Assets?

MoonLake Immunotherapeutics's Change In Prepaid Assets for the quarter that ended in Mar. 2024 was $-0.83 Mil. It means MoonLake Immunotherapeutics's Prepaid Assets declined by $0.83 Mil from Dec. 2023 to Mar. 2024 .

MoonLake Immunotherapeutics's Change In Prepaid Assets for the fiscal year that ended in Dec. 2023 was $-6.35 Mil. It means MoonLake Immunotherapeutics's Prepaid Assets declined by $6.35 Mil from Dec. 2022 to Dec. 2023 .


MoonLake Immunotherapeutics Change In Prepaid Assets Historical Data

The historical data trend for MoonLake Immunotherapeutics's Change In Prepaid Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MoonLake Immunotherapeutics Change In Prepaid Assets Chart

MoonLake Immunotherapeutics Annual Data
Trend Dec21 Dec22 Dec23
Change In Prepaid Assets
- -2.73 -6.35

MoonLake Immunotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Prepaid Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 -0.89 0.65 -7.22 -0.83

MoonLake Immunotherapeutics Change In Prepaid Assets Calculation

Change In Prepaid Assets is any increase or decrease between periods of the prepaid assets.

Change In Prepaid Assets for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MoonLake Immunotherapeutics Change In Prepaid Assets Related Terms

Thank you for viewing the detailed overview of MoonLake Immunotherapeutics's Change In Prepaid Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Business Description

Traded in Other Exchanges
Address
Dorfstrasse 29, Zug, CHE, 6300
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
Executives
Matthias Bodenstedt officer: Chief Financial Officer DORFSTRASSE 29, ZUG V8 6300
Bihua Chen 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iv Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Simon Sturge director DORFSTRASSE 29, ZUG V8 6300
Kristian Reich officer: Chief Scientific Officer DORFSTRASSE 29, ZUG V8 6300
Santos Da Silva Jorge director, officer: Chief Executive Officer DORFSTRASSE 29, ZUG V8 6300
Bvf Partners L P/il director, 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Andrew John Phillips director C/O CORMORANT ASSET MANAGEMENT, LLP, 200 CLARENDON STREET, FL 52, BOSTON MA 02116
Ramnik Xavier director DORFSTRASSE 29, ZUG V8 6300
Spike Loy director DORFSTRASSE 29, ZUG V8 6300
Kara Lassen director DORFSTRASSE 29, ZUG V8 6300

MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Headlines

From GuruFocus